PURPOSE: The overexpression of cyclooxygenase 2 (COX-2) gene, also known as prostaglandin-endoperoxide synthase 2 ( PTGS2), occurs in breast cancer, but whether it affects response to anticox drugs remains unclear. We investigated the relationships between PTGS2 expression, celecoxib use during neoadjuvant chemotherapy (NAC), and both event-free survival (EFS) and overall survival (OS). MATERIALS AND METHODS: We analyzed a cohort of 156 patients with human epidermal growth factor receptor 2 -negative breast cancer from the REMAGUS02 (ISRCTN Registry No. 10059974) trial with pretreatment PTGS2 expression data. Patients were treated by sequential NAC (epirubicin plus cyclophosphamide followed by docetaxel with or without celecoxib). Experimental validation was performed on breast cancer cell lines. The Cancer and Leukemia Group B (CALGB) 30801 ( ClinicalTrials.gov identifier: NCT01041781) trial that tested chemotherapy with or without celecoxib in patients with lung cancer served as an independent validation cohort. RESULTS: After 94.5 months of follow-up, EFS was significantly lower in the celecoxib group (hazard ratio [HR], 1.7; 95% CI, 1 to 2.88; P = .046). A significant interaction between PTGS2 expression and celecoxib use was detected ( Pinteraction = .01). In the PTGS2-low group (n = 100), EFS was lower in the celecoxib arm (HR, 3.01; 95% CI, 1.45 to 6.24; P = .002) than in the standard treatment arm. Celecoxib use was an independent predictor of poor EFS, distant relapse-free survival, and OS. Celecoxib in addition to docetaxel enhanced cell viability in PTGS2-low cell lines but not in PTGS2-high cell lines. In CALGB 30801, a trend toward poorer progression-free survival was observed in the patients with low urinary metabolite of prostaglandin E2 who received celecoxib (HR = 1.57; 95% CI, 0.87 to 2.84; P = .13). CONCLUSION: Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors. COX-2 inhibitors should preferably be avoided during docetaxel use in patients with breast cancer who are undergoing NAC.
PURPOSE: The overexpression of cyclooxygenase 2 (COX-2) gene, also known as prostaglandin-endoperoxide synthase 2 ( PTGS2), occurs in breast cancer, but whether it affects response to anticox drugs remains unclear. We investigated the relationships between PTGS2 expression, celecoxib use during neoadjuvant chemotherapy (NAC), and both event-free survival (EFS) and overall survival (OS). MATERIALS AND METHODS: We analyzed a cohort of 156 patients with humanepidermal growth factor receptor 2 -negative breast cancer from the REMAGUS02 (ISRCTN Registry No. 10059974) trial with pretreatment PTGS2 expression data. Patients were treated by sequential NAC (epirubicin plus cyclophosphamide followed by docetaxel with or without celecoxib). Experimental validation was performed on breast cancer cell lines. The Cancer and Leukemia Group B (CALGB) 30801 ( ClinicalTrials.gov identifier: NCT01041781) trial that tested chemotherapy with or without celecoxib in patients with lung cancer served as an independent validation cohort. RESULTS: After 94.5 months of follow-up, EFS was significantly lower in the celecoxib group (hazard ratio [HR], 1.7; 95% CI, 1 to 2.88; P = .046). A significant interaction between PTGS2 expression and celecoxib use was detected ( Pinteraction = .01). In the PTGS2-low group (n = 100), EFS was lower in the celecoxib arm (HR, 3.01; 95% CI, 1.45 to 6.24; P = .002) than in the standard treatment arm. Celecoxib use was an independent predictor of poor EFS, distant relapse-free survival, and OS. Celecoxib in addition to docetaxel enhanced cell viability in PTGS2-low cell lines but not in PTGS2-high cell lines. In CALGB 30801, a trend toward poorer progression-free survival was observed in the patients with low urinary metabolite of prostaglandin E2 who received celecoxib (HR = 1.57; 95% CI, 0.87 to 2.84; P = .13). CONCLUSION:Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors. COX-2 inhibitors should preferably be avoided during docetaxel use in patients with breast cancer who are undergoing NAC.
Authors: Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Zafrani; Marie-Christine Mathieu; Philippe Bertheau; Jean Marc Guinebretière; Marc Spielmann; Alexia Savignoni; Michel Marty Journal: Breast Cancer Res Treat Date: 2010-05-18 Impact factor: 4.872
Authors: A S Hamy; I Bieche; J Lehmann-Che; V Scott; Ph Bertheau; J M Guinebretière; M C Matthieu; B Sigal-Zafrani; O Tembo; M Marty; B Asselain; F Spyratos; P de Cremoux Journal: Breast Cancer Res Treat Date: 2016-09-03 Impact factor: 4.872
Authors: Ari Ristimäki; Anna Sivula; Johan Lundin; Mikael Lundin; Tiina Salminen; Caj Haglund; Heikki Joensuu; Jorma Isola Journal: Cancer Res Date: 2002-02-01 Impact factor: 12.701
Authors: Martin J Edelman; Dee Watson; Xiaofei Wang; Carl Morrison; Robert A Kratzke; Scott Jewell; Lydia Hodgson; Ann M Mauer; Ajeet Gajra; Gregory A Masters; Michelle Bedor; Everett E Vokes; Mark J Green Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Cesare Gridelli; Ciro Gallo; Anna Ceribelli; Vittorio Gebbia; Teresa Gamucci; Fortunato Ciardiello; Francesco Carozza; Adolfo Favaretto; Bruno Daniele; Domenico Galetta; Santi Barbera; Francesco Rosetti; Antonio Rossi; Paolo Maione; Francesco Cognetti; Antonio Testa; Massimo Di Maio; Alessandro Morabito; Francesco Perrone Journal: Lancet Oncol Date: 2007-06 Impact factor: 41.316
Authors: Anna Fishbein; Weicang Wang; Haixia Yang; Jun Yang; Victoria M Hallisey; Jianjun Deng; Sanne M L Verheul; Sung Hee Hwang; Allison Gartung; Yuxin Wang; Diane R Bielenberg; Sui Huang; Mark W Kieran; Bruce D Hammock; Dipak Panigrahy Journal: Proc Natl Acad Sci U S A Date: 2020-08-14 Impact factor: 11.205
Authors: Andrew W Chung; Anthony J Kozielski; Wei Qian; Jianying Zhou; Ann C Anselme; Alfred A Chan; Ping-Ying Pan; Delphine J Lee; Jenny C Chang Journal: NPJ Breast Cancer Date: 2022-03-08
Authors: Diana Valentina Tudor; Adrian Florea; Mihai Cenariu; Diana Elena Olteanu; Marius Farcaș; Andreea Hopârtean; Simona Valeria Clichici; Gabriela Adriana Filip Journal: J Clin Med Date: 2022-08-04 Impact factor: 4.964
Authors: Shang-Jui Wang; Karishma Khullar; Sinae Kim; Nikhil Yegya-Raman; Jyoti Malhotra; Roman Groisberg; Samuel H Crayton; Ann W Silk; John L Nosher; Michael A Gentile; Janice M Mehnert; Salma K Jabbour Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751